Pipeline

Advancing GC-C agonist therapies

A focused portfolio built on the proven GC-C mechanism to address gastrointestinal diseases.

TRULANCE® (plecanatide)

Approved therapy for adults with CIC and IBS-C; foundation for our GC-C expertise.

Product overview →

Dolcanatide

Investigational candidate in development for ulcerative colitis leveraging GC-C agonism.

Learn about dolcanatide →

Commitment to compliance: All programs follow rigorous clinical protocols and safety oversight. For approved TRULANCE therapy, review the Important Safety Information below.

Important Safety Information — TRULANCE® (plecanatide)

Indication

TRULANCE is indicated for the treatment of adults with chronic idiopathic constipation (CIC) and adults with irritable bowel syndrome with constipation (IBS-C).

Contraindications

TRULANCE is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. Do not use in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings & Precautions

Diarrhea is the most common adverse reaction. If severe diarrhea occurs, suspend dosing and contact a healthcare provider. Safety and efficacy have not been established in patients under 18 years of age; avoid use in pediatric patients.

Additional Information

Use TRULANCE only as prescribed. Discuss all medical conditions, medications, and pregnancy or breastfeeding considerations with a healthcare professional. See product pages for complete details.

View full product overview →

Advancing GC-C agonist therapies

Pipeline at a glance

TRULANCE® (plecanatide)

Dolcanatide